D-4559 / Ashvattha Therap - LARVOL DELTA

A potent macrophage switching drug D-4559 reduces tumor GROWTH in a hepatocellular carcinoma mouse model (AACR 2023) - "Tumor-associated macrophages (TAMs) play a role in cancer progression and are associated with Sorafenib resistance in hepatocellular carcinoma (HCC)1. D-4559 significantly increased M1 infiltration, shifted TAM polarization from M2 to M1 phenotype and favored pro-inflammatory cytokines suggesting that D-4559 creates an immunopermissive tumor microenvironment leading to a reduction in tumor growth. This preclinical study supports the development of the potent macrophage switching drug D-4559 as a safe and effective agent that can be used systemically for the treatment of HCC or in combination therapies to improve anti-tumor immune response."

Late-breaking abstract • Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • CXCL8 • FLT1 • TNFA

Ashvattha Therapeutics Presented Promising Preclinical Data on Novel Macrophage Switching Nanomedicine D-4559 at AACR Annual Meeting (GlobeNewswire) - "Data demonstrated D-4559 switches tumor associated macrophages from an M2 to M1 pro-inflammatory phenotype leading to reduction in tumor growth in a mouse model of hepatocellular carcinoma....The data supports development of the potent macrophage switching drug as a potentially safe and effective agent that can be used systemically for the treatment of hepatocellular carcinoma or in combination therapies to improve anti-tumor immune response."

Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

Ashvattha Therapeutics to Present Preclinical Data at the AACR and ARVO 2023 Annual Meetings (GlobeNewswire) - "Ashvattha Therapeutics...announced that the company will present preclinical data at the upcoming American Association for Cancer Research (AACR) and the Association for Research in Vision and Ophthalmology (ARVO) 2023 annual meetings....Preclinical data to be presented at AACR will showcase the potential effect of D-4559, a potent macrophage switching nanomedicine, on reducing tumor growth in a mouse model of hepatocellular carcinoma, a type of liver cancer."

Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor